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Abstract 
Background: Infectious diseases are associated with an increase in the risk of developing insulin 
resistance and subsequent diabetes mellitus due to a possible role of chronic inflammation. While this 
relationship is well established for viral infections like hepatitis C or hepatitis B, little is known about the 
association of herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) with diabetes 
mellitus. 
Methods: We conducted a cross-sectional study using the data from the 2007-2016 cycle of the 
National Health and Nutrition Examination Survey. Participants from the age group of 18-49 years with 
valid diabetes mellitus and HSV-1 and HSV-2 results and who completed the interview and examination 
were eligible for the analysis. HSV-1 and HSV-2 were defined by type specific enzymatic immunodot 
assay as positive or negative. Diabetes status was defined by glycohemoglobin level (HbA1c) as 
euglycemic (≤5.6%), prediabetes (5.7-6.4%), and diabetes (≥6.5%); participants who self-reported being 
diabetic were considered as having diabetes regardless of their HBA1c levels. We conducted logistic 
regression analysis to estimate the crude and adjusted odds ratio and 95% confidence interval of 
diabetes mellitus comparing participants with positive HSV-1 and HSV-2 to those with negative HSV-1 
and HSV-2. 
Results: The prevalence of HSV-1 among participants with diabetes was 67.2% (95% CI 62.3,72.0), and 
the prevalence of HSV-2 among participants with diabetes was 26.9% (95% CI 23.2,30.7). The prevalence 
of diabetes among participants with HSV-1 infection was 5.7% (95% CI 5.1,6.3), and the prevalence of 
diabetes among HSV-2 infection was 7.9% (95% CI 6.8,8.9). After adjusting for confounding factors, the 
odds of diabetes versus euglycemia among participants with HSV-1 was 1.05 (95% CI 0.9,1.2), and odds 
of diabetes versus euglycemia among participants with HSV 2 was 1.1 (95% CI 0.9,1.2). 
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Conclusion: After controlling for potential confounders, HSV-1 and HSV-2 infections are not  associated 
with diabetes mellitus in the US population aged 18-49 years, 2007-2016 
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CHAPTER 1 
INTRODUCTION 
Background 
There is a growing concern about the increasing prevalence of major public health conditions like 
diabetes mellitus and its co-infections. Even though herpes simplex virus (HSV) is not a major public 
health concern yet, in 2012 herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) 
was prevalent in 67%  and 11% respectively of the global population under the age of 50 years (1). In 
2015-2016 according to National Health and Nutrition Examination Survey (NHANES), the national 
estimates of prevalence by age, sex, and race among persons aged 14-49 years in the US for HSV-1 were 
47.8% while HSV-2 was 11.9%. (2) 
HSV is one of the members of a large group of double stranded DNA viruses called the Herpesviridae 
family and is of two types HSV-1 and HSV-2. It frequently causes ulcerative vesicular mucocutaneous 
lesions in human beings. HSV 1 is most commonly transmitted through non-sexual contact like contact 
with sores, saliva or surfaces around the mouth. Lesions occur on lips, inside the mouth, or on the face. 
They are commonly found in children and young adults. Recently HSV-1 has also been associated with 
genital herpes due to oral-genital contact. HSV-2 is a more common type. It is characterized by lesions 
on the genital surfaces as it is commonly transmitted by sexual contact. Rarely, it can also be 
transmitted from infected mothers to neonates during the delivery (3, 4).   
Previous studies reported that chronic viral infections like hepatitis B and hepatitis C are associated with 
the pathogenesis of diabetes mellitus, likely due to increases in pro-inflammatory cytokines like tumor 
necrosis factor alpha, interferon-gamma and lymphocytic cell infiltration (5). This persistent chronic 
inflammatory state in the body increases insulin resistance, which subsequently leads to the 
development of diabetes mellitus (6-8). Similarly, a study conducted by Theil, D. and colleagues have 
found evidences that suggest the ability of HSV-1 and HSV-2 to establish latency in sensory neuronal 
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ganglia was responsible for increasing the pro-inflammatory cytokines and development of chronic 
inflammatory response during re-activation of virus (9) . Thus, a possible biological hypothesis can be 
made that there is an association between HSV-1 and HSV-2 with diabetes mellitus.  
Previous cross-sectional studies reported an association between HSV-1 and HSV-2 infections with 
diabetes mellitus. A study conducted by Sun, Y. and colleagues in 2005 found a significant association of 
diabetes with HSV-1 infection [adjusted odds ratio (aOR) 1.5% 95% CI 1.1-2.0] (10). Ghane, M. also 
investigated the frequency of HSV infection with diabetes mellitus using PCR and ELISA and found a 
relationship between them (11). However, a study conducted by Lutsey, P. L. and colleagues in 2009 
found no association between diabetes and HSV infection (aOR 1.5% 95% CI 0.68-3.28) (12)  
Research Gap and Purpose of the Study 
Evidence indicates that viral infections may contribute to the pathogenesis of diabetes (8, 13, 14). 
However, limited studies have been conducted to explore the association between HSV-1 or HSV-2 and 
diabetes mellitus, and they do not show consistent results. Using the data from 2007-2016, we 
hypothesize that HSV-1 and HSV-2 are associated with diabetes mellitus. The objective of this study is to 
determine the association between HSV-1 and HSV-2 and the prevalence of diabetes mellitus and pre-
diabetes in the US adult population. 
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CHAPTER II 
REVIEW OF LITERATURE 
Diabetes Mellitus 
In recent years, there has been tremendous growth in the prevalence of type 1 and type 2 diabetes 
mellitus worldwide, and it has become the seventh leading cause of death in the United States. 
According to the US Centers for Disease Control and Prevention (CDC), 30.3 million Americans had 
diabetes in 2015, while 84 million had pre-diabetes and at increased risk of diabetes (15). Diabetes is 
characterized by an abnormal increase in blood glucose concentration. Several risk factors have been 
identified for the incidence of diabetes, such as age, sedentary lifestyle, genetic susceptibility, and 
environmental factors (16, 17). However, obesity is known to be a major risk factor that predisposes an 
individual to diabetes (18). Obesity is found to increase the levels of pro-inflammatory cytokines such as 
tumor necrosis factor alpha or interferon-gamma (19) These elevated levels of cytokines increase the 
risk of developing insulin resistance and subsequent diabetes mellitus (6).  
Studies conducted by J. C. Pickup and colleagues reported that diabetes mellitus is associated with 
chronic inflammation that is characterized by increase in the pro-inflammatory cytokines or innate 
immune response (20) Other studies and reviews also suggests diabetes mellitus be associated with 
elevated levels of C-reactive proteins, Interferon-gamma, Interleukin-6 and tumor necrosis factor alpha 
(20-23) Evidence from the study conducted by Sestan, M., and colleagues in 2018 reports that elevated 
levels of interferon-gamma in viral infection downregulates the insulin receptors of skeletal muscles and 
thus virally induced inflammation develops insulin resistance and subsequent diabetes mellitus (8, 24). 
Choi and colleagues in 2018, Kiernan, K. in 2018 and Mason Al. and colleagues in 1999 also suggest a 
possible association of viral infections with chronic inflammation and subsequent pathogenesis of 
diabetes mellitus (7, 8, 14) 
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Herpes Simplex Virus 
Herpes simplex virus (HSV) causes infectious diseases characterized by ulcerative and vesicular lesions, 
which can be complicated by life-threatening necrotizing herpes-simplex encephalitis. HSV type 1 (HSV-
1) is usually non-sexually transmitted, and the lesions are commonly present on the face, around the 
mouth or on the neck and less frequently on genital areas due to oral-genital contact. HSV type 2 (HSV-
2) is a sexually transmitted infection that causes lesions in the anal and genital areas of the body. HSV-1 
and HSV-2 have an affinity towards nerve cells and are known to establish, after primary infection, 
lifelong latency in the sensory neuronal ganglia (4, 25). Reactivation may occur due to conditions that 
cause immunosuppression like AIDS, surgery or trauma, mental and physical stress (9). 
According to the world health organization, in 2012, HSV-1 and HSV-2 were prevalent in 67% and 11% 
respectively of the global population under the age of 50 years (1). The national estimates from the 
National Health and Nutrition Examination Survey (NHANES) show HSV-1 to be prevalent in 48.7% and 
HSV-2 in 11.9% of the US population (2). 
HSV-1 and HSV-2 infections are found to be associated with the development of a chronic inflammatory 
state in the body due to its ability to remain latent for a long time. A study conducted by Theil, D., and 
colleagues provided evidence for elevated levels of CD8 cells, interferon-gamma, and tumor necrosis 
factor-alpha in an individual latently infected by HSV infection (9). Animal studies reported that upon 
reactivation of HSV infection, immune response elevates the pro-inflammatory cytokines like interferon-
gamma in the host (5).  
Co-occurring of Herpes Simplex Virus infection and Diabetes Mellitus 
Based on the evidence that associates chronic inflammation with diabetes and HSV-1 and HSV-2 
infections, we can biologically hypothesize that HSV-1 and HSV-2 are associated with the pathogenesis 
of diabetes mellitus through the mechanism of chronic inflammation. The state of persistent chronic 
inflammation in the body may arise due to latent HSV infection and its frequent reactivation resulting in 
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elevated levels of pro-inflammatory cytokines. These cytokines may further lead to the development of 
insulin resistance, followed by diabetes mellitus. 
There is little in the literature that explores the association between HSV-1 and HSV-2 with diabetes 
mellitus, and the results are inconsistent. A cross-sectional study conducted by Sun and colleagues has 
found the significant association between HSV-1 and diabetes with an adjusted odds ratio (aOR) of 1.5% 
and 95% C.I. of 1.1-2.0 (10). They controlled for risk factors such as hypertension, cholesterol, age, and 
sex. Ghane also investigated the frequency of HSV infection with diabetes mellitus using PCR and ELISA 
testing and found a relationship between them (11) But, another cross-sectional study conducted by 
Lutsey and colleagues in 2009 found no association between HSV infection and diabetes (aOR 1.5% 95% 
C.I. 0.68-3.28) after controlling for demographic characteristics (12) 
Summary of literature review 
Highlights from the literature review of previous studies include: 
1. Globally there is growing concern regarding the co-occurrence of viral infections and diabetes 
mellitus. 
2. Immune activation due to viral infection may result in chronic systemic inflammation, which is directly 
linked to the pathogenesis of insulin resistance and subsequent type 2 diabetes mellitus. 
3. Viral infections like hepatitis B and C are associated with diabetes mellitus. 
4. Viral infections like HSV-1 and HSV-2 are responsible for the development of the chronic inflammatory 
state during latent and active periods and therefore, may be associated with the prevalence of diabetes 
mellitus. 
5. Only two studies found an association between HSV-1 and HSV-2 infections and diabetes mellitus. 
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6. Prospective studies are required to better characterize the association between HSV-1 and HSV-2 
infections and diabetes mellitus. 
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CHAPTER 3 
MANUSCRIPT 
Introduction 
According to the World Health Organization, 67% of the global population under 50 years of age has 
Herpes Simplex virus type 1 (HSV-1) infection, and 11% has Herpes Simplex virus type 2 (HSV-2) 
infection. (26). In 2015-2016, the prevalence of HSV 1 in the United States was 47.8%, and the 
prevalence of HSV 2 was 11.9% (2). HSV-1 is transmitted non-sexually via contact with sores, saliva or 
surfaces around the mouth of an infected individual. Transmission of HSV-1 occurs most commonly 
during childhood and may cause recurrent orolabial and facial lesions. However, recently, HSV-1 
infection has also cause genital lesions due to oral-genital contact (1). HSV-2 is transmitted sexually and 
typically includes ulcerative and vesicular lesions on genital or anal areas (1) (27). Rarely, HSV-2 can also 
be transferred from mother to neonate during vaginal delivery and is potentially life-threatening (28). 
While behavioral risk factors associated with HSV 1 and HSV 2 infections are well established, additional 
individual factors and comorbidities that may increase the risk of HSV are poorly understood. (1) (28)    
Given the rapid global increases in non-communicable diseases (NCDs), there is a growing concern over 
the synergy between co-occurring infectious diseases with NCDs. Infectious diseases that persist latently 
in the host for long periods may contribute to chronic inflammation over the life course (9). Both HSV 1 
and HSV 2 infections can establish lifelong latency in neuronal sensory ganglia (5, 29). Reactivation of 
HSV 1 and HSV 2 infections may trigger innate inflammatory responses in the body which in turn can 
promote inflammatory cytokines like interleukin 6, tumor necrosis factor alpha, interferon beta and 
interferon-gamma (type 1 and type 2 interferons) (5) and could contribute to chronic systemic 
inflammation. The role of chronic inflammation in the pathogenesis of insulin resistance and subsequent 
diabetes mellitus incidence is well established (8). In addition, other viral infections which contribute to 
the systemic inflammation are associated with diabetes mellitus. 
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Despite of accumulating evidence indicating viral infections may contribute to diabetes pathogenesis (7, 
8, 14, 30), there is limited evidence regarding the association between HSV-1 and HSV-2 infections with 
the risk of developing diabetes mellitus. In this study, we aimed to determine the association between 
prevalence of HSV-1 and HSV-2 infections with the prevalence of diabetes mellitus and pre-diabetes 
using cross-sectional data from the US National Health and Nutrition Examination Survey (NHANES) 
study, 2007-2016.   
Methods 
Study Design and Overview 
We performed a cross-sectional analysis using NHANES 2007-2016 data, which included five continuous 
cycles. Briefly, NHANES is a nationally representative health examination survey that includes in-person 
interviews and a health examination administered by trained medical personnel. Detailed information 
on NHANES methodology has been published in the literature previously (31).  During 2007-2016, 
50,588 NHANES individuals were selected for participation, and 48,710 participants completed the 
interview and physical examinations (32).  The exposures for this analysis were HSV-1 and HSV-2, and 
the outcome for the study was Diabetes Mellitus. 
Participant Eligibility Criteria and Laboratory Methods 
Eligible participants included adults aged 18 to 49 years who completed the NHANES interview, and 
underwent a health examination, had a valid measure of diabetes and had a valid HSV-1 and HSV-2 lab 
result. Serum specimens for HSV-1 and HSV-2 infections were tested using Type specific Enzymatic 
Immunodot Assay to detect antibodies reactive to HSV-1 and HSV-2 infections. Participants with missing 
or indeterminate HSV-1 and HSV-2 Immunodot Assay results were excluded.  
Diabetes mellitus was defined by glycated hemoglobin (HbA1c) levels in combination with self-reported 
diabetes status. Those with missing and indeterminate results for HbA1c were excluded from the 
analysis to avoid the assumption of results. Glycohemoglobin levels were measured using standardized 
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Glyco-analyzers. Finally, a total of n=14,638 participants were eligible for HSV-1 analyses, and n=14,618 
participants were eligible for HSV-2 analyses.  
 
Variables and Study measures  
HSV-1 and HSV-2 were interpreted based on the US CDC guidelines for type-specific serologic testing. (4)  
Participants who self-reported to have a history of diagnosis of diabetes by a healthcare professional 
were considered diabetes regardless of their HbA1c level. Those with missing or no history of self-
reported diabetes were then categorized using glycated hemoglobin levels (HbA1c) as euglycemic 
(<5.6%), pre-diabetes (5.7-6.4%), or diabetes (>=6.5%) according to the American Diabetes Association 
guidelines (16). 
Total cholesterol, current smoking status, lifetime smoking status, sexual behavior by age when had first 
sex, condom use during sex, number of sex partners per year and lifetime, history of genital herpes and 
history of circumcision were some of the covariates included in the analysis. Total cholesterol levels 
were characterized as desirable (<200 mg/dl), borderline high (200-239 mg/dl) and high (>=240mg/dl) 
based on the guidelines developed by National Institute of Health- National Cholesterol Education 
Program (33). Smoking status was defined in two ways, current smoking status, and lifetime smoking 
status. We categorized the current smoking status of the participant's non-smokers, every day smokers, 
and someday, smokers based on their self-reported responses for currently smoking. Lifetime smoking 
status was defined as smokers if participants smoked atleast100 cigarettes in a lifetime and are currently 
smoking, as former smokers if participants smoked at least 100 cigarettes in a lifetime but currently not 
smoking and as non-smokers if participants had not smoked at least 100 cigarettes in a lifetime and they 
currently do not smoke. (34), (35).  
We characterized sexual behavior using self-reported measures that included the age of first sex, 
number of sexual partners, use of condom during sex and history of genital herpes. The age when had 
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first sex was categorized as before the age of 15 years, between the age of 15-18 years and after the age 
of 18 years. Use of condom during sex was categorized as never use a condom, always use a condom, 
and sometimes use a condom. Sexual partners per year and sexual partners in a lifetime were 
categorized as no partners, single partner, two partners, three to five partners, and more than six 
partners. History of Genital Herpes diagnosis by a health professional was self-reported by the 
participants as yes or no. Similarly, circumcision history for males was self-reported as yes or no by the 
participant. 
Statistical Analysis 
The association between HSV-1 and HSV-2 with diabetes mellitus was assessed using bivariate analyses 
and multivariable logistic regression. In the bivariate analysis, the Rao-Scott chi-square test was used to 
assess for potential confounders. We reported weighted prevalence estimates and their 95% confidence 
intervals (CI) to examine the prevalence of HSV-1, HSV-2, and diabetes status in relation with included 
participant characteristics. The unadjusted association was examined using prevalence differences and 
crude odds ratios (cOR). Adjusted odds ratio (aOR) and 95% CI for both exposure-outcome pairs were 
estimated using multivariable logistic regression models and were adjusted for potential confounders 
(36). We used four different models for logistic regression. Model 1 as odds of diabetes and pre-diabetes 
versus euglycemic, model 2 as odds of diabetes versus pre-diabetes and euglycemic, model 3 as odds of 
diabetes versus euglycemic and model 4 as odds of pre-diabetes versus euglycemic. Covariate selection 
criteria included previous study findings, bivariate association analysis, and causal model theory 
(directed acyclic graphs) (37). Statistical Analytical Software (SAS) 9.4 version was used to conduct the 
analysis. To produce unbiased variance estimates, in the complex datasets of NHANES during analysis, 
we used the proposed weighting methodology and guidelines set forth by National Center for Health 
Statistics, Centers for Disease Control and Prevention (38). The weight variable used during analysis to 
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calculate the measures of associations, prevalence estimates, and confidence intervals was WTMEC2YR.  
Statistical significance for all the tests was determined by a two-sided p-value of <0.05. 
Results 
Study Participants 
Before accounting for a corrected variance by using selection weights, from those with valid diabetes 
and HSV-1 results, 831 eligible participants had diabetes, and 600 of them were HSV-1 positive. Among 
those 831, 267 were HSV-2 positive (Figure 1). 
Prevalence of HSV 1&2  
The overall prevalence estimates of HSV-1 among adults in the total US population between 2007-2016 
was 55.2% (95%CI 53.2,57.3%) and the overall prevalence estimate of HSV-2 was 15.9% (95%CI 
14.9,16.9) (Table 1). The prevalence for HSV-1 was highest among Hispanics (74.3% 95%CI 68.3,72.4) 
followed by A1c level >6.5% (69.1% 95% CI 63.4,74.7), males with circumcision (68.2% 95%CI 65.1,71.3) 
and participants with diabetes (67.2% 95%CI 62.3,72.0). The prevalence estimates of HSV-2 among 
adults in the US population for the year 2007-2016 was 15.9% (95% CI 14.9,16.9). They were highest for 
Non-Hispanic Blacks 40.9% (95%CI 39.1,42.8) followed by participants with diabetes (26.9% 95%CI 
23.2,30.7) and current smokers (23.9% 95% CI 22.1,25.8) (Table 1) 
Prevalence of Diabetes Mellitus 
The estimated prevalence of diabetes among US adult population between 2007-2016 was 4.7% (95% CI 
4.2,5.1). The prevalence estimate for diabetes was highest among participants with the diagnosis of 
hypertension (13.3% 95% CI 11.8,14.9) followed by Body Mass Index > 30kg/sq. m (obese) (9.7% 95% CI 
8.7,10.7), age group 41-50 years (9.1% 95% CI 7.9,10.4), HSV-2 positive (7.9% 95% CI 6.8,8.9), HSV-1 
positive (5.7% 95% CI 5.1,6.3) and Non-Hispanic Blacks (7.5% 95% CI 8.7, 10.7). (Table 2) 
Prevalence Difference in diabetes mellitus  
The prevalence estimate of diabetes was higher among participants with positive HSV-1 infection by 2.3 
percentage points (95% CI 1.4,3.1) as compared to participants with negative HSV-1 infection. The 
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prevalence estimate of diabetes was higher among participants with positive HSV-2 infection by 3.8 
percentage points (95% CI 2.7,5.0) as compared to participants with negative HSV-2 infection. (Table 1, 
Table 2) 
Logistic regression model results 
We conducted logistic regression analysis to examine the crude and the adjusted association between 
adults with HSV-1 and HSV-2 and diabetes. Four different models for odds of diabetes, prediabetes, and 
euglycemia were examined to assess the association for different outcome variables with HSV-1 and 
HSV-2 (Table 3).  Before adjusting for potential confounders, the odds of diabetes and pre-diabetes 
versus euglycemia among those with HSV-1 infection was 1.8 times (95% CI 1.6,1.9) the odds of diabetes 
and pre-diabetes among those with no HSV-1 infection. While odds of diabetes and pre-diabetes among 
those with HSV-2 infection was two times (95% CI 1.8,2.3), the odds of diabetes and pre-diabetes among 
those with no HSV-2 infection. Similar results were observed for other models as well. (Table 3) 
After adjusting for covariates in the multivariable models, the odds of diabetes and pre-diabetes among 
those with HSV-1 infection was equal to odds of diabetes and pre-diabetes among those with no HSV-1 
infection (aOR 1.1 95% CI 0.9,1.2). Similarly, the odds of diabetes and pre-diabetes among those with 
HSV-2 infection was equal to odds of diabetes and pre-diabetes among those with no HSV-2 infection 
(aOR 1.1 95% CI 0.9,1.2). (Table 3)  
Sensitivity Analysis 
In our sensitivity analysis, we reported the range of odds ratios after adjusting for multiple combinations 
of covariates in the models. The adjusted odds ratios for diabetes and prediabetes vs. euglycemia 
ranged from 1.03 (95% CI 0.8,1.3) to 1.4 (95% CI 0.9,1.5) among adults with HSV-1 (Table 4). For adults 
with HSV-2, the adjusted odds of diabetes versus prediabetes and euglycemia ranged from 1.1 (95% CI 
0.9,1.4) to 1.5 (95% CI 1.04,1.6) (Table 4). Model adjusted for age, sex, BMI, total cholesterol and 
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hypertension showed odds of diabetes and pre-diabetes to be statistically significant for both HSV-1 
(aOR 1.4% 95% CI 1.3, 1.5) and HSV-2 infections (aOR 1.5% 95% CI 1.3, 1.7) (Table 4). 
Discussion 
We attempted to examine the association between HSV-1 and HSV-2 infections and diabetes mellitus. 
We found a strong crude association of HSV-1 and HSV-2 with diabetes. The prevalence of HSV-1 among 
adults with diabetes was 14.4% points more than the adults with euglycemia and prevalence of HSV-2 
among adults with diabetes was 12.9% points more than those with euglycemia. The prevalence of 
diabetes was also significant among adults with HSV-1 positive and HSV-2 positive as compared to 
negative. After adjusting for confounders, there was no association between HSV-1 and HSV-2 and 
diabetes mellitus. In the model that adjusted age, sex, hypertension, total cholesterol, and BMI, the 
association was present (aOR 1.4% for HSV-1 and aOR 1.5% for HSV-2). These covariates are a part of 
metabolic syndrome, and thus, this finding gives an insight into possible confounding by metabolic 
syndrome and a possible association of HSV-1 and HSV-2 infections with metabolic syndrome. Further 
studies are required to explore this association.  Our study includes data of 10 years (2007-2016) from a 
nationally representative sample of US from NHANES and thus to our knowledge, this is the largest and 
most generalizable study comparing HSV-1 and HSV-2 infections with diabetes mellitus among US 
adults.  
The results of our study are inconsistent with the findings of previous studies. A randomized cross-
sectional study conducted by Sun, Y. Et al. in 2005 on patients of Beijing Fu Wai heart hospital found a 
significant association with an adjusted odds ratio of diabetes as 1.5 (95% CI 1.1-2.0) for HSV-1 infection 
(10). However, the study was conducted in a clinical setting and thus did not have a large sample size. 
Also, the study was not generalizable to the US population. Another randomized cross-sectional study 
conducted by Lutsey and colleagues in 2009 reported an adjusted odds ratio of 1.5% (95% CI 0.68,3.28) 
and concluded as no association between HSV infection and diabetes in a sample of multiethnic study of 
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atherosclerosis participants. The study, however, controlled for only demographic variables and not the 
potential confounding risk factors like sexual behavior, total cholesterol, hypertension, and BMI (12). 
Although only two studies were conducted to investigate the direct association between HSV-1 and 
HSV-2 with diabetes, there are many studies and reviews that have established an association between 
viral infection and insulin resistance with subsequent diabetes mellitus (8, 13, 14). A cross-sectional 
study conducted by Mason, A. et al. in 2003 on patients from St. Louis and New Orleans have found that 
Hepatitis C virus (HCV) infection was an independent predictor of diabetes mellitus (p=.02) and was 
suggested as an additional risk factor for the development of diabetes (14). Hepatitis B virus (HBV) and 
Hepatitis C virus were also found to be associated with diabetes in a cohort study conducted by H. Y. 
Choi et al. in 2017 on the population of Korea with the adjusted Hazard Ratio for diabetes as 1.4 and 
1.68 in HBV and HCV groups, respectively (7). These hypotheses of viral infections increasing the risk for 
diabetes mellitus may explain how HSV-1 and HSV-2 infections may increase the risk of diabetes and 
vice-versa. 
Our study was subjected to several limitations. First, this is a cross-sectional study. We could only find an 
association between HSV-1 and HSV-2 infections and diabetes. But because we had no data that could 
indicate the time of HSV infection in reference to the diagnosis of diabetes, we were not able to 
determine if the observed association was due to increased risk of diabetes from HSV-1 and HSV-2 
infections or the risk of developing HSV-1 and HSV-2 infections due to diabetes mellitus. Another 
limitation is that there may have been misclassification of outcome variable diabetes. We did not define 
diabetes based on oral glucose tolerance test (OGTT), which is the gold standard test according to ADA 
guidelines (16). HbA1c test and possibility of inaccurate self-reported diabetes status could have 
distorted our estimated association between HSV-1 and HSV-2 and diabetes mellitus. There may have 
also been misclassification of patient characteristics. For example, variables such as smoking or sexual 
behavior have a social stigma attached to it. Therefore, the self-reported responses from participants 
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might not be accurate. Information on whether the HSV infection was new or active, latent, or dormant 
was not available. There may have been possible confounding by other factors involved in metabolic 
syndrome, which were not included in the analysis due to lack of data. Our study cannot be generalized 
to the older population of the US as the older age group (>50 years of age) was not included in the 
analysis. Lastly, the Hepatitis C virus has been found to increase the risk of developing type 2 diabetes 
(39). We did not consider the history of hepatitis C virus antibody seropositivity, which may have 
confounded the relationship between HSV-1 and HSV-2 and diabetes. To understand the relationship in 
detail, prospective studies exploring the association and direction of the association between HSV-1 and 
HSV-2 and diabetes mellitus are needed.  
Conclusion 
The results from our study reported that before controlling for potential confounders, the prevalence of 
HSV-1 and HSV-2 infections was significantly associated with an increase in the odds of diabetes 
prevalence in US adults aged 18-49 years. After controlling for confounders, there was no association 
between HSV-1 and HSV-2 infections with diabetes mellitus. Overall, the prevalence of HSV-1 and HSV-2 
was higher among diabetes and prediabetes patients as compared to patients with euglycemia. And the 
prevalence of diabetes was also higher among patients with HSV-1 and HSV-2 infections as compared to 
patients without HSV-1 and HSV-2 infections. This study gives an insight into a possible association of 
non-communicable chronic diseases like diabetes mellitus with viral infections like HSV-1 and HSV-2. 
With increasing public health concern for diabetes and HSV infections worldwide, further research may 
be needed to identify the associations of potential risk factors. 
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Figure 1 
Flow chart describing the process of selection for NHANES 2007-2016 participants eligible 
for the study, including the categorization of eligible participants by diabetes status, raw 
numbers not weighted for NHANES methodology 
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Figure 2 
Directed Acyclic Graph for the covariates associated with HSV-1 and diabetes mellitus 
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Figure 3 
Directed Acyclic Graph for the covariates associated with HSV-2 and diabetes mellitus 
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Table 1:  
Distribution of Exposure ‘Herpes Simplex Virus 1 ’ by Characteristics for the sample with 
valid DM results in NHANES 2007-2016  
  HSV TYPE 1  
N= 14638 
  
Characteristics HSV 1 positive 
Prevalence estimates   
% (95% CI) 
HSV 1 negative 
Prevalence estimates 
 % (95% CI) 
Prevalence 
Difference and 
95% CI 
P value 
Rao-
Scott Chi 
test 
Total population % 55.2 (53.2,57.3) 44.8 (42.7,46.8)   
Age (Years) 
Median (Q3 - Q1) 
18-30 
31-40 
41-50 
 
 
36 (43 - 27) 
44.1 (41.7,46.4) 
60.3 (57.7,62.8) 
65.2 (62.4,68.0) 
 
 
29 (38 - 22) 
55.9 (53.6,58.3) 
39.7 (37.2,42.3) 
34.8 (31.9,37.6) 
 
 
Reference 
16.2 (13.6,18.9) 
21.2 (18.7,23.7) 
<0.0001 
Gender 
Male 
Female 
Missing 
 
52.3 (49.9,54.5) 
58.2 (55.9,60.5) 
 
47.7 (45.5,50.0) 
41.8 (39.5,44.1) 
 
-5.9 (-7.9,-3.9) 
Reference 
<0.0001 
Race/Ethnicity 
Non-Hispanic White 
Non-Hispanic Black 
Other 
Missing 
 
46.9 (44.6,49.2) 
62.5 (59.7,65.2) 
70.4 (68.3,72.4) 
 
 
53.1 (50.8,55.4) 
37.5 (34.8,40.3) 
29.7 (27.6,31.7) 
 
 
Reference 
15.6 (12.8,18.3) 
23.5 (20.8,26.1) 
 
<0.0001 
HbA1c (%)2 
Median (Q3 - Q1) 
<5.7 
5.7-6.5 
>6.5 
Missing 
 
5.4 (5.1 - 5.6) 
52.8 (50.7,54.9) 
66.2 (63.4,68.9) 
69.1 (63.4,74.7) 
 
5.3 (5.5 , 5.0) 
47.2 (45.1,49.3) 
33.8 (31.1,36.6) 
30.9 (25.3,36.6) 
 
 
Reference 
13.3 (10.9,15.8) 
16.2 (10.6,21.8) 
<0.0001 
DM status (A1c+Self report)3 
Euglycemia 
Prediabetes 
Diabetes 
 
 
52.8 (50.7,54.9) 
66.4 (63.7,69.1) 
67.2 (62.3,72.0) 
 
 
47.2 (45.1,49.3) 
33.6 (30.9,36.3) 
32.9 (27.9,37.7) 
 
 
Reference 
13.6 (11.1,16.1) 
14.4 (9.7,18.9) 
<0.0001 
BMI4 
<18.5 
18.5-24.9 
25.0-29.9 
>=30.0 
Missing 
 
48.4 (41.2,55.4) 
49.5 (46.9,52.2) 
56.0 (53.6,58.5) 
60.2 (57.6,62.8) 
65.3 (53.2,77.3) 
 
51.6 (44.6,58.7) 
50.5 (47.8,53.1) 
43.9 (41.5,46.4) 
39.8 (37.2,42.4) 
34.7 (22.7,46.8) 
 
Reference 
1.2 (-5.5,7.8) 
7.7 (0.5,14.9) 
11.9 (4.5,19.2) 
16.9 (4.4,29.4) 
<0.0001 
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Total cholesterol (mg/dl)5 
<200 
200-239 
>=240 
Missing 
 
 
53.1 (50.9,55.3) 
58.9 (56.4,61.4) 
59.4 (55.3,63.6) 
100.0 (100,100) 
 
 
46.9 (44.7,49.1) 
41.1 (38.6,43.6) 
40.6 (36.4,44.7) 
--------------------- 
 
 
Reference 
5.8 (3.2,8.4) 
6.3 (2.6,10.1) 
46.9 (44.7,49.1) 
<0.0001 
Marital Status 
Never married 
Married 
Missing 
 
47.2 (44.8,49.5) 
59.7 (57.1,62.2) 
52.3 (49.2,55.5) 
 
52.8 (50.5,55.2) 
40.3 (37.8,42.9) 
47.7 (44.5,50.9) 
 
Reference 
12.5 (9.7,15.2) 
5.1 (1.7,8.6) 
<0.0001 
Current Smoking status6 
No Smoking 
Smoking 
Missing 
 
57.4 (53.9,60.9) 
60.9 (58.4,63.4) 
52.6 (50.2,54.9) 
 
42.6 (39.1,46.0) 
30.1 (36.6,41.6) 
47.4 (45.1,49.7) 
 
Reference 
3.5 (-0.3,7.3) 
-4.8 (-8.0,-1.6) 
<0.0001 
Smoking status-Lifetime7 
Never Smoker 
Current Smoker 
Former Smoker 
Missing 
 
 
53.6 (51.2,56.1) 
60.9 (58.4,63.4) 
57.4 (53.9,60.9) 
35.1 (30.3,39.8) 
 
 
 
46.4 (43.9,48.8) 
39.1 (36.6,41.6) 
42.6 (39.1,46.0) 
64.9 (60.1,69.7 
 
 
Reference 
7.3 (4.6,10.0) 
3.8 (0.5,7.1) 
-18.6 (-23.9,-13.2) 
<0.0001 
Hypertension8 
No Hypertension 
Yes Hypertension 
Missing 
 
53.8 (51.6,55.9) 
62.6 (58.8,65.5) 
79.7 (60.8,98.5) 
 
46.2 (44.0,48.4) 
37.4 (34.5,40.2) 
20.3 (1.5,39.2) 
 
Reference 
8.8 (5.9,11.8) 
25.9 (6.8,44.9) 
<0.0001 
SB - Age of 1st sex9 
18-27 yrs 
28-37 yrs 
38-49 yrs 
Missing 
 
55.2 (53.1,57.2) 
50.9 (41.5,60.5) 
61.3 (30.9,91.7) 
55.8 (52.4,59.2) 
 
44.8 (42.8,46.9) 
49.0 (39.5,58.5) 
38.7 (8.3,69.1) 
44.8 (42.8,46.9) 
 
Reference 
-4.2 (-13.5,5.1) 
6.2 (-24.8,37.1) 
0.7 (-2.2,3.5) 
0.7692 
SB- Protection Use10 
Always 
Never  
Sometimes  
Missing 
 
61.5 (58.3,64.8) 
55.1 (52.7,57.5) 
50.3 (47.7,52.9) 
55.7 (52.9,58.6) 
 
38.5 (35.2,41.7) 
44.9 (42.5,47.3) 
49.7 (47.1,52.3) 
44.3 (41.4,47.1) 
 
Reference 
-6.4 (-9.2,-3.6) 
-11.2 (-14.9,-7.6) 
-5.8 (-9.2,-2.4) 
<0.0001 
SB - Sex partners / Year11 
No partner 
One partner 
Two partners 
3-5 partners 
>6 partners 
Missing 
 
 
49.8 (46.9,52.7) 
56.1 (53.8,58.4) 
56.1 (51.9,60.3) 
47.0 (42.3,51.7) 
54.6 (46.7,62.4) 
61.5 (57.8,65.2) 
 
 
50.2 (47.3,53.1) 
43.9 (41.6,46.2) 
43.9 (39.7,48.1) 
52.9 (48.3,57.7) 
45.4 (37.6,53.3) 
38.5 (34.8,42.2) 
 
 
Reference 
6.3 (3.4,9.2) 
6.3 (1.5,10.9) 
-2.8 (-7.6,2.0) 
4.8 (-2.9,12.5) 
11.7 (8.4,14.9) 
<0.0001 
SB - Sex Partners in Lifetime14 
No partner 
One partner 
Two partners 
 
 
54.3 (50.3,58.2) 
45.4 (41.6,49.2) 
 
 
45.7 (41.8,49.7) 
54.6 (50.8,58.4) 
 
 
Reference 
-8.8 (-13.9,-3.8) 
<0.0001 
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3-5 partners 
>6 partners 
Missing 
53.6 (49.6,57.7) 
54.8 (51.4,58.1) 
57.9 (55.5,60.2) 
61.5 (57.8,65.2) 
46.4 (42.3,50.4) 
45.2 (41.9,48.5) 
42.1 (39.8,44.5) 
38.5 (34.8,42.2) 
-0.6 (-6.0,4.8) 
0.5 (-4.4,5.4) 
3.6 (-0.9,8.1) 
7.3 (2.8,11.7) 
SB- Doctor told to have Genital 
Herpes15 
No 
Yes 
Missing 
 
 
55.1 (53.1,57.2) 
54.1 (47.5,60.7) 
55.9 (52.6,59.3) 
 
 
44.9 (42.8,46.9) 
45.9 (39.3,52.5) 
44.0 (40.7,47.4) 
 
 
Reference 
-1.0 (-7.8,5.7) 
0.8 (-2.1,3.7) 
0.8100 
SB- Male circumcision status16 
No 
Yes 
Missing  
 
 
68.2 (65.1,71.3) 
47.7 (45.2,50.3) 
57.6 (55.2,59.9) 
 
 
31.8 (28.7,34.9) 
52.3 (49.7,54.8) 
42.4 (40.1,44.8) 
 
 
Reference 
-20.5 (-24.4,-16.5) 
-10.6 (-14.1,-7.2) 
<0.0001 
Hepatitis C virus RNA17 
Negative 
Positive 
Missing 
 
76.1 (65.6,86.5) 
66.1 (54.9,77.3) 
55.0 (52.9,57.1) 
 
23.9 (13.5,34.4) 
33.9 (22.7,45.1) 
44.9 (42.9,47.0) 
 
Reference 
-9.9 (-1.7,21.6) 
-21.0 (10.3,31.8) 
0.0007 
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Table 2: 
Distribution of Exposure ‘Herpes Simplex Virus 2 ’ by Characteristics for the sample with 
valid DM results in NHANES 2007-2016  
 
 
 HSV TYPE 2 
N=14618 
  
Characteristics HSV 2 positive 
Prevalence estimates  
% (95% CI) 
HSV 2 negative 
Prevalence estimates  
% (95% CI) 
Prevalence 
Difference and 
95% CI 
P value 
Rao-
Scott Chi 
test 
Total population % 15.9 (14.9,16.9) 84.1 (83.1,85.1)   
Age (Years) 
Median (Q3 - Q1) 
18-30 
31-40 
41-50 
 
 
39 (44 - 32) 
8.1 (7.1,9.1) 
17.8 (16.2,19.4) 
24.6 (22.4,26.9) 
 
32 (40 - 24) 
91.9 (90.9,92.9) 
82.2 (80.6,83.8) 
75.4 (73.1,77.6) 
 
 
 
Reference 
9.6 (7.9,11.4) 
16.6 (14.1,18.9) 
 
<0.0001 
Gender 
Male 
Female 
 
10.6 (9.7,11.5) 
21.1 (19.7,22.5) 
 
89.4 (88.5,90.3) 
78.9 (77.5,80.2) 
 
-10.5 (-11.7,-9.3) 
Reference 
<0.0001 
Race/Ethnicity 
Non-Hispanic White 
Non-Hispanic Black 
Other 
Missing 
 
11.9 (10.8,13.2) 
40.9 (39.1,42.8) 
13.6 (12.4,14.9) 
 
88.0 (86.8,89.2) 
59.0 (57.2,60.9) 
86.4 (85.2,87.6) 
 
 
Reference 
28.9 (26.7,31.1) 
1.6 (-0.2,3.5) 
 
<0.0001 
HbA1c (%)2 
Median (Q3 - Q1) 
<5.7 
5.7-6.5 
>6.5 
Missing 
 
5.4 (5.7 - 5.2) 
14.1 (13.0,15.1) 
24.1 (21.7,26.4) 
26.9 (22.6,31.3) 
 
5.3 (5.6 - 5.1) 
85.9 (84.9,86.9) 
75.9 (73.6,78.3) 
73.1 (68.8,77.4) 
 
 
Reference 
10.0 (7.6,12.4) 
12.8 (8.5,17.1) 
<0.0001 
DM status (A1c+Self report)3 
Euglycemia 
Prediabetes 
Diabetes 
 
14.0 (12.9,15.1) 
23.9 (21.6,26.3) 
26.9 (23.2,30.7) 
 
85.9 (84.9,87.0) 
76.1 (73.8,78.4) 
73.1 (69.3,76.8) 
 
Reference 
9.9 (7.5,12.3) 
12.9 (9.1,16.7) 
<0.0001 
BMI4 
<18.5 
18.5-24.9 
25.0-29.9 
>=30.0 
Missing 
 
11.2 (6.7,15.7) 
11.7 (10.4,12.9) 
16.6 (15.2,17.9) 
19.8 (17.9,21.6) 
13.1 (7.6,18.6) 
 
88.9 (84.4,93.4) 
88.3 (87.0,89.6) 
83.4 (82.1,84.8) 
80.2 (78.4,82.1) 
86.9 (81.4,92.4) 
 
Reference 
0.5 (-4.0,5.0) 
5.4 (0.6,10.2) 
8.6 (3.7,13.6) 
1.9 (-4.5,8.4) 
<0.0001 
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Total cholesterol (mg/dl)5 
<200 
200-239 
>=240 
Missing 
 
14.6 (13.4,15.7) 
18.6 (16.9,20.3) 
17.9 (15.6,20.1) 
30.2 (0.00,89.5) 
 
85.5 (84.3,86.6) 
81.4 (79.9,84.4) 
82.1 (79.9,84.4) 
69.8 (10.5,100.0) 
 
Reference 
4.0 (2.2,5.8) 
3.3 (0.9,5.7) 
15.6 (-44.0,-75.3) 
<0.0001 
Marital Status 
Never married 
Married 
Missing 
 
14.4 (12.8,16.1) 
17.1 (15.9,18.4) 
14.1 (12.2,15.9) 
 
85.6 (83.9,87.2) 
82.9 (81.6,84.2) 
85.9 (84.1,87.8) 
 
Reference 
2.7 (0.8,4.6) 
-0.4 (-2.3, 1.5) 
0.0023 
Current Smoking status6 
No Smoking 
Smoking 
Missing 
 
17.4 (15.2,19.6) 
23.9 (22.1,25.8) 
12.6 (11.6,13.6) 
 
82.6 (80.4,84.8) 
76.1 (74.2,77.9) 
87.4 (86.4,88.4) 
 
Reference 
6.6 (4.1,9.0) 
-4.8 (-6.9,-2.7) 
<0.0001 
Smoking status-Lifetime7 
Never Smoker 
Current Smoker 
Former Smoker 
Missing 
 
13.2 (12.1,14.3) 
23.9 (22.0,25.8) 
17.4 (15.2,19.6) 
2.4 (1.5,3.3) 
 
86.8 (85.7,87.9) 
76.1 (74.2,77.9) 
82.6 (80.4,84.8) 
97.6 (96.7,98.5) 
 
Reference 
10.7 (8.9,12.6) 
4.2 (2.0,6.3) 
-10.8 (-12.2,-9.4) 
<0.0001 
Hypertension8 
No Hypertension 
Yes Hypertension 
Missing 
 
14.5 (13.5,15.4) 
23.4 (20.9,25.9) 
19.4 (0.00,40.7) 
 
85.5 (84.6,86.5) 
76.6 (74.1,79.1) 
80.6 (59.3,100.0) 
 
Reference 
8.9 (6.6,11.2) 
4.9 (-16.5,26.3) 
<0.0001 
SB - Age of 1st sex9 
18-27 yrs 
28-37 yrs 
38-49 yrs 
Missing 
 
16.6 (15.4,17.7) 
4.9 (1.7,8.2) 
22.1 (2.3,41.9) 
13.2 (11.7,14.8) 
 
83.5 (82.3,84.6) 
95.0 (91.8,98.3) 
77.9 (58.1,97.7) 
86.8 (85.2,88.3) 
 
Reference 
-11.6 (-14.9,-8.3) 
5.6 (-14.2,25.3) 
-3.4 (-5.0,-1.7) 
<0.0001 
SB- Protection Use10 
Always 
Never  
Sometimes  
Missing 
 
17.3 (15.3,19.3) 
16.6 (14.9,18.3) 
14.9 (13.4,16.5) 
14.8 (13.4,16.2) 
 
82.7 (80.7,84.7) 
83.4 (81.7,85.0) 
85.0(83.5,86.6) 
85.2 (83.8,86.6) 
 
Reference 
-0.7 (-2.9,1.5) 
-2.4 (-4.8,0.01) 
-2.5 (-4.8,-0.4) 
0.0514 
SB - Sex partners / Year11 
No partner 
One partner 
Two partners 
3-5 partners 
>6 partners 
Missing 
 
16.6 (14.5,18.7) 
14.9 (13.7,16.1) 
19.9 (16.5,23.2) 
18.1 (15.2,20.9) 
16.4 (11.7,21.1) 
16.6 (14.7,18.6) 
 
83.4 (81.3,85.5) 
85.1 (83.9,86.3) 
80.1 (76.8,83.5) 
81.9 (79.1,84.8) 
83.6 (78.9,88.3) 
83.4 (81.4,85.3) 
 
Reference 
-1.7 (-4.1,0.7) 
3.3 (-0.4,6.9) 
1.5 (-1.9,4.8) 
-0.02 (-5.2,4.8) 
0.00 (-2.5,2.5) 
0.0061 
SB - Sex Partners in Lifetime14 
No partner 
One partner 
Two partners 
3-5 partners 
>6 partners 
Missing 
 
15.4 (13.1,17.7) 
7.9 (6.3,9.6) 
10.4 (8.3,12.5) 
14.8 (12.9,16.6) 
20.9 (19.4,22.5) 
16.8 (14.8,18.9) 
 
84.6 (82.4,86.9) 
92.1 (90.5,93.7) 
89.6 (87.5,91.8) 
85.2 (83.4,87.0) 
79.1 (77.5,80.6) 
83.2 (81.2,85.2) 
 
Reference 
-7.5 (-10.3,-4.6) 
-4.9 (-8.4,-1.6) 
-0.6 (-3.5,2.4) 
5.6 (2.8,8.4) 
1.5 (-1.4,4.3) 
<0.0001 
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SB- Doctor told to have Genital 
Herpes15 
No 
Yes 
Missing 
 
 
14.3 (13.3,15.4) 
68.3 (61.9,74.7) 
13.2 (11.7,14.8) 
 
 
85.7 (84.7,86.7) 
31.7 (25.3,38.0) 
86.8 (85.2,99.3) 
 
 
Reference 
54.0 (47.8,60.3) 
-1.1 (-2.8,0.6) 
<0.0001 
SB- Male circumcision status16 
No 
Yes 
Missing 
 
11.2 (9.6,12.8) 
10.8 (9.6,11.9) 
19.9 (18.5,21.2) 
 
88.8 (87.2,90.4) 
89.2 (88.1,90.4) 
80.1 (78.8,81.5) 
 
Reference 
-0.5 (-2.5,1.6) 
8.7 (6.8,10.6) 
<0.0001 
Hepatitis C virus RNA17 
Negative 
Positive 
Missing 
 
24.5 (12.1,36.9) 
49.8 (37.2,62.4) 
15.6 (14.6,16.7) 
 
75.5 (63.1,87.9) 
50.2 (37.6,62.4) 
84.4 (83.3,85.4) 
 
Reference 
25.3 (10.3,40.3) 
-8.9 (-21.5,3.6) 
<0.0001 
 
Table 1 Abbreviations: HbA1c-Glycated Hemoglobin; DM status- Diabetes Mellitus Status; BMI-Body 
Mass Index; SB- Sexual behavior, HSV1-Herpes Simplex Virus type 1, HSV 2- Herpes Simplex Virus type 2 
1: Ratio of family income to poverty guidelines; poverty guidelines are determined by the Department of 
Health, and Human Services used as poverty measure to calculate the ratio of family income to poverty. 
2: HbA1c categories as determined by the American Diabetes Association. 
3: Diabetes Mellitus Status as determined by American Diabetes Association guidelines for HbA1c level 
and self-reported (those who answered ‘yes’ to having been told by a doctor or health professional that 
he/she had diabetes). Participants who self-reported as diabetes were classified as having diabetes 
regardless of HbA1c and participants with HbA1c level as diabetes were classified as diabetes regardless 
of self-reporting. 
4: BMI categories as determined by CDC guidelines. 
5: Total Cholesterol categorized by National Institute of Health guidelines. 
6: Current Smoking Status defined by self-reporting if now smoking cigarettes. 
7: Smoking status of a lifetime defined by self-reporting of having smoked at least 100 cigarettes in their 
lifetime. Currently smoking at least one cigarette every day or some days and have smoked at least 100 
cigarettes in the past; formerly smoked at least 10 cigarettes in their lifetime but are not smoking 
currently at all; Never smoked at least 100 cigarettes in their lifetime. 
8: Hypertension self-reported by participants as ‘yes’ to having been told by a doctor or a health 
professional that he/she had hypertension/high blood pressure. 
9: Sexual behavior defined by self-reporting of the age of having 1st sex in a lifetime.  
10: Sexual behavior defined by self-reporting of having used protection (Condom) while having sex; 
Participants who always used protection; participants who never use any protection and participants 
who sometimes use protection. 
11: Sexual Behavior defined by self-reporting of a number of sex partners per year. Participants 
categorized as No partner, one partner per year, two partners per year, three to five partners per year, 
and more than six partners per year.  
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12: Herpes Simplex Virus Type 1 test results determined by testing participant serum for antibodies to 
herpes simplex type 1. The test was conducted by the National Health and Nutrition Examination 
Survey, US. 
13: Herpes Simplex Virus Type 2 test results determined by testing participant serum for antibodies to 
herpes simplex type 2. The test was conducted by the National Health and Nutrition Examination 
Survey, US. 
14. Sexual behavior defined by self-reporting of a number of sexual partners in a lifetime.  Participants 
categorized as No partner, one partner, two partners, three to five partners, and more than six partners 
in a lifetime.  
15. Sexual behavior defined by self-reporting of doctor ever told to have Genital herpes.  
16. Sexual behavior defined by self-reporting of male circumcision status. 
17.  Hepatitis C virus RNA defined by the results of in vitro nucleic acid amplification test conducted by 
National Health and Nutrition Examination Survey, US. 
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Table 3:  
Distribution of outcome diabetes mellitus, prediabetes and no diabetes by characteristics 
for sample with valid DM results in NHANES 2007-2016 
Characteristics Diabetes (2) 
Prevalence 
Estimates % 
(95% CI) 
Prediabetes (1) 
Prevalence 
Estimates 
 % (95% CI) 
Euglycemia (0) 
Prevalence 
Estimates % (95% 
CI) 
Prevalence 
Difference for 
Diabetes (2)  
5 (95% CI) 
P value 
Rao-
Scott Chi 
test 
Total population % 4.7 (4.2,5.1) 13.0 (12.3,13.8) 82.3 (81.4,83.2)   
Age 
Median (Q3 - Q1) 
18-30 
31-40 
41-50 
 
42 (46 - 42) 
1.4 (1.1,1.7) 
4.6 (3.9,5.2) 
9.1 (7.9,10.4) 
 
 
39 (45 - 31) 
6.8 (6.1,7.4) 
13.8 (12.6,14.9) 
20.8 (19.3,22.4) 
 
 
31 (40 - 24) 
91.8 (91.1,92.5) 
81.7 (80.3,83.1) 
70.0 (67.9,72.1) 
 
 
Reference 
3.1 (2.5,3.8) 
7.7 (6.5,8.9) 
<0.0001 
Gender 
Male 
Female 
 
4.9 (4.3,5.6) 
4.4 (3.9,4.9) 
 
14.0 (13.2,14.9) 
12.1 (11.1,13.1) 
 
81.3 (79.9,82.2) 
83.5 (82.4,84.7) 
 
0.6 (-0.2,1.3) 
Reference 
0.0016 
Race/Ethnicity 
Non-Hispanic White 
Non-Hispanic Black 
Other 
 
3.5 (2.9,4.1) 
7.5 (6.5,8.6) 
5.9 (5.0,6.8) 
 
9.6 (8.6,10.6) 
24.9 (23.2,26.7) 
15.5 (14.6,16.4) 
 
86.9 (85.7,88.1) 
67.5 (65.6,69.5) 
78.6 (77.3,79.9) 
 
Reference 
4.0 (2.8,5,3) 
2.4 (1.3,3.4) 
<0.0001 
BMI4 
<18.5 
18.5-24.9 
25.0-29.9 
>=30.0 
Missing 
 
0.8 (0.05,1.51) 
 1.3 (1.9,1.6) 
3.0 (2.5,3.6) 
9.7 (8.7,10.7) 
7.4 (2.9,11.9) 
 
6.2 (3.2,9.2) 
6.3 (5.5,7.2) 
11.6 (10.5,12.6) 
21.2 (19.7,22.7) 
18.3 (10.1,24.4) 
 
93.1 (89.8,96.3) 
92.4 (91.5,93.3) 
85.4 (84.2,86.7) 
69.1 (67.2,70.9) 
74.3 (65.9,82.9) 
 
Reference 
0.5 (-0.3,1.3) 
2.2 (1.3,3.2) 
8.9 (7.6,10.2) 
6.7 (2.3,11.0) 
<0.0001 
Total cholesterol (mg/dl)5 
<200 
200-239 
>=240 
Missing 
 
4.2 (3.7,4.7) 
4.8 (3.9,5.7) 
7.1 (5.8,8.5) 
---------------- 
 
10.7 (9.8,11.6) 
16.3 (15.1,17.6) 
19.9 (17.5,22.4) 
30.2 (0.00,89.5) 
 
85.1 (84.0,86.2) 
78.8 (77.2,80.5) 
72.9 (70.3,75.6) 
69.8 (10.5,100) 
 
Reference 
0.6 (-0.4,1.5) 
2.9 (1.6,4.2) 
 
<0.0001 
HSV 1 12 
Negative 
Positive 
 
3.4 (2.8,3.9) 
5.7 (5.1,6.3) 
 
9.8 (8.9,10.7) 
15.7 (14.8,16.6) 
 
86.8 (85.7,87.9) 
78.6 (77.6,79.7) 
 
Reference 
2.3 (1.4,3.1) 
<0.0001 
HSV 213 
Negative 
Positive 
 
4.1 (3.6,4.5) 
7.9 (6.8,8.9) 
 
11.8 (11.2,12.5) 
19.6 (17.5,21.8) 
 
84.2 (83.3,85.0) 
72.5 (69.8,75.1) 
 
Reference 
3.8 (2.7,5.0) 
<0.0001 
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Marital Status 
Never married 
Married 
Missing 
 
3.6 (2.9,4.3) 
5.7 (4.9,6.4) 
2.7 (2.1,3.4) 
 
10.5 (9.4,11.7) 
14.7 (13.8,15.7) 
11.1 (9.5,12.6) 
 
85.9 (84.6,87.1) 
79.6 (78.3,80.8) 
86.2 (84.4,87.9) 
 
Reference 
2.1 (1.1,3.1) 
-0.9 (-1.8,0.05) 
<0.0001 
Current Smoking status6 
No Smoking 
Smoking 
Missing 
 
6.3 (4.9,7.7) 
5.0 (4.1,5.9) 
4.1 (3.6,4.6) 
 
13.1 (11.2,14.9) 
16.1 (14.6,17.7) 
11.9 (11.1,12.8) 
 
80.7 (78.4,82.9) 
78.8 (77.1,80.6) 
83.9 (82.9,85.0) 
 
Reference 
-1.3 (-2.9,0.4) 
-2.2 (-3.6,-0.7) 
<0.0001 
Smoking status-Lifetime7 
Never Smoker 
Current Smoker 
Former Smoker 
Missing 
 
4.3 (3.8,4.8) 
5.0 (4.1,5.9) 
6.3 (4.9,7.7) 
1.2 (0.4,1.9) 
 
12.2 (11.3,13.2) 
16.1 (14.6,17.7) 
13.1 (11.2,14.9) 
6.4 (4.7,8.2) 
 
83.5 (82.3,84.6) 
78.8 (77.1,80.6) 
80.7 (78.4,82.9) 
92.4 (90.6,94.2) 
 
Reference 
0.7 (-0.4,1.8) 
1.9 (0.6,3.4) 
-3.1 (-4.0,-2.2) 
<0.0001 
Hypertension8 
No Hypertension 
Yes Hypertension 
Missing 
 
2.9 (2.6,3.4) 
13.3 (11.8,14.9) 
6.1 (0.00,17.9) 
 
11.6 (10.9,12.2) 
20.7 (18.6,22.8) 
13.6 (0.00,29.6) 
 
85.4 (84.6,86.9) 
65.9 (63.5,68.4) 
80.3 (60.3,100) 
 
Reference 
10.3 (8.8,11.8) 
3.1 (-8.7,14.9)  
<0.0001 
SB - Age of 1st sex9 
18-27 yrs 
28-37 yrs 
38-49 yrs 
Missing 
 
4.7 (4.2,5.2) 
5.4 (2.3,8.5) 
2.9 (0.00,9.1) 
4.5 (3.7,5.3) 
 
12.8 (11.9,13.7) 
19.2 (12.5,25.9) 
33.9 (5.4,62.4) 
13.7 (12.2,15.2) 
 
82.5 (81.4,83.6) 
75.3 (68.3,82.4) 
63.1 (34.5,91.8) 
81.8 (80.8,83.4) 
 
Reference 
0.7 (-2.3,3.8) 
-1.7 (7.9,4.5) 
-0.2 (-1.2,0.8) 
0.402 
SB- Protection Use10 
Always use condom 
Never use condom 
Sometimes use condom 
Missing 
 
4.7 (3.7,5.7) 
4.5 (3.7,5.2) 
3.6 (2.9,4.4) 
5.8 (5.0,6.6) 
 
 
15.8 (14.4,17.2) 
12.2 (11.1,13.4) 
10.3 (8.9,11.5) 
15.0 (13.8,16.2) 
 
79.5 (77.9,81.2) 
83.3 (81.9,84.6) 
86.1 (84.5,87.7) 
79.2 (77.8,80.6) 
 
Reference 
-0.2 (-1.4,1.0) 
-1.0 (-2.2,0.2) 
1.1 (-0.1,2.4) 
<0.0001 
SB - Sex partners / Year11 
No partner 
One partner 
Two partners 
3-5 partners 
>6 partners 
 Missing 
 
5.8 (4.8,6.8) 
4.7 (4.1,5.3) 
3.4 (2.4,4.4) 
3.0 (1.9,4.1) 
3.8 (0.9,6.8) 
4.7 (3.6,5.7) 
 
12.9 (11.2,14.6) 
13.1 (12.2,14.0) 
11.1 (8.6,13.5) 
11.9 (9.3,14.5) 
11.2 (6.9,15.6) 
14.9 (13.1,16.8) 
 
81.4 (79.6,83.1) 
82.2 (81.0,83.4) 
85.6 (82.8,88.3) 
85.1 (82.2,87.9) 
84.9 (79.8,90.1) 
80.4 (78.4,82.5) 
 
1.1 (0.01,2.2) 
Reference 
-1.3 (-2.5,-0.1) 
-1.7 (-2.7,-0.6) 
-0.9 (-3.9,2.1) 
0.0 (-1.3,1.2) 
<0.0001 
SB - Sex Partners in Lifetime14 
No partner 
One partner 
Two partners 
3-5 partners 
>6 partners 
 
4.2 (3.3,5.1) 
4.3 (3.2,5.3) 
3.8 (2.5,5.2) 
4.4 (3.5,5.3) 
5.5 (4.6,6.4) 
 
11.0 (9.3,12.8) 
11.8 (10.2,13.4) 
12.1 (9.7,14.6) 
13.1 (11.3,14.9) 
14.2 (12.9,15.4) 
 
84.8 (82.8,86.8) 
83.9 (82.2,85.6) 
84.1 (81.1,87.0) 
82.5 (80.3,84.6) 
80.3 (78.8,81.9) 
 
-0.1 (-1.4,1.3) 
Reference 
-0.5 (-2.0,1.1) 
0.1 (-1.1,13.7) 
1.2 (-0.1,2.5) 
0.0029 
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Missing 4.6 (3.6,5.6) 14.9 (13.1,16.8) 80.5 (78.4,82.5) 0.3 (=1.2,1.9) 
SB- Doctor told to have Genital 
Herpes15 
No 
Yes 
Missing 
 
 
4.7 (4.2,5.2) 
4.3 (2.2,6.4) 
4.5 (3.7,5.3) 
 
 
12.9 (12.1,13.8) 
12.8 (8.7,16.8) 
13.7 (12.2,15.2) 
 
 
82.4 (81.3,83.4) 
82.9 (78.4,87.4) 
81.8 (80.2,83.4) 
 
 
Reference 
-0.4 (-2.5,1.7) 
-0.2 (-1.2,0.8) 
0.9195 
SB- Male Circumcision status16 
No 
Yes 
Missing  
 
5.6 (4.3,7.0) 
4.6 (3.8,5.5) 
4.5 (4.1,4.9) 
 
17.0 (15.0,18.9) 
13.0 (12.0,14.1) 
12.4 (11.4,13.3) 
 
77.4 (74.9,79.8) 
82.3 (80.9,83.7) 
83.1 (81.9,84.2) 
 
Reference 
-1.0 (-2.7,0.7) 
-1.1 (-2.5,0.4) 
0.0003 
Hepatitis C virus RNA17 
Negative 
Positive 
Missing 
 
8.1 (0.0,16.7) 
6.9 (1.5,12.5) 
4.6 (4.2,5.1) 
 
16.8 (7.4,26.1) 
21.6 (12.8,30.3) 
12.9 (12.3,13.7) 
 
75.1 (63.6,86.6) 
71.5 (62.7,80.3) 
82.4 (81.5,83.3) 
 
Reference 
-1.2 (-8.0,5.6) 
-3.5 (-12.0,4.9) 
0.0834 
 
Table 2 Abbreviations: HbA1c-Glycated Hemoglobin; DM status- Diabetes Mellitus Status; BMI-Body 
Mass Index; SB- Sexual behavior, HSV1-Herpes Simplex Virus type 1, HSV 2- Herpes Simplex Virus type 2 
1: Ratio of family income to poverty guidelines; poverty guidelines are determined by the Department of 
Health, and Human Services used as poverty measure to calculate the ratio of family income to poverty. 
2: HbA1c categories as determined by the American Diabetes Association. 
3: Diabetes Mellitus Status as determined by American Diabetes Association guidelines for HbA1c level 
and self-reported (those who answered ‘yes’ to having been told by a doctor or health professional that 
he/she had diabetes). Participants who self-reported as diabetes were classified as having diabetes 
regardless of HbA1c and participants with HbA1c level as diabetes were classified as diabetes regardless 
of self-reporting. 
4: BMI categories as determined by CDC guidelines. 
5: Total Cholesterol categorized by National Institute of Health guidelines. 
6: Current Smoking Status defined by self-reporting if now smoking cigarettes. 
7: Smoking status of a lifetime defined by self-reporting of having smoked at least 100 cigarettes in their 
lifetime. Currently smoking at least one cigarette every day or some days and have smoked at least 100 
cigarettes in the past; formerly smoked at least 10 cigarettes in their lifetime but are not smoking 
currently at all; Never smoked at least 100 cigarettes in their lifetime. 
8: Hypertension self-reported by participants as ‘yes’ to having been told by a doctor or a health 
professional that he/she had hypertension/high blood pressure. 
9: Sexual behavior defined by self-reporting of the age of having 1st sex in a lifetime.  
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10: Sexual behavior defined by self-reporting of having used protection (Condom) while having sex; 
Participants who always used protection; participants who never use any protection and participants 
who sometimes use protection. 
11: Sexual Behavior defined by self-reporting of a number of sex partners per year. Participants 
categorized as No partner, one partner per year, two partners per year, three to five partners per year, 
and more than six partners per year.  
12: Herpes Simplex Virus Type 1 test results determined by testing participant serum for antibodies to 
herpes simplex type 1. The test was conducted by the National Health and Nutrition Examination 
Survey, US. 
13: Herpes Simplex Virus Type 2 test results determined by testing participant serum for antibodies to 
herpes simplex type 2. The test was conducted by the National Health and Nutrition Examination 
Survey, US. 
14. Sexual behavior defined by self-reporting of a number of sexual partners in a lifetime.  Participants 
categorized as No partner, one partner, two partners, three to five partners, and more than six partners 
in a lifetime.  
15. Sexual behavior defined by self-reporting of doctor ever told to have Genital herpes.  
16. Sexual behavior defined by self-reporting of male circumcision status. 
17.  Hepatitis C virus RNA defined by   the results of in vitro nucleic acid amplification test conducted by 
National Health and Nutrition Examination Survey, US 
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Table 4:   
Multivariable model for the odds of diabetes mellitus in US population aged 18-49 years, 
2007-2016 
 
 
 
 
Models Crude Odds Ratio 
(95% CI) for Diabetes 
 
Adjusted Odds Ratio 
(95% CI)1 for Diabetes 
Adjusted Odds Ratio 
(95% CI) for diabetes 
controlling for age, 
race, and gender  
Model 1 Odds of Diabetes and Prediabetes vs. Odds of Euglycemia 
HSV 12 (N=14638) 
Positive 
Negative 
 
1.8 (1.6,1.9) 
Reference 
 
1.1 (0.9,1.2) 
Reference 
 
1.1 (1.1,1.4) 
Reference 
HSV 23 (N=14618) 
Positive 
Negative 
 
2.0 (1.8,2.3) 
Reference 
 
1.05 (0.9,1.2) 
Reference 
 
1.2 (1.1,1.4) 
Reference 
Model 2 Odds of Diabetes vs. Odds of Prediabetes and Euglycemia 
 
HSV 12 (N=14638) 
Positive 
Negative 
 
1.70 (1.4, 2.1) 
Reference 
 
1.02 (0.8,1.3) 
Reference 
 
1.15 (0.9,1.4) 
Reference 
HSV 23 (N=14618) 
Positive 
Negative 
 
2.03 (1.7,2.5) 
Reference 
 
1.1 (0.9,1.4) 
Reference 
 
1.2 (1.1,1.6) 
Reference 
Model 3 Odds of Diabetes vs. Odds of Euglycemia 
HSV 12 (N=12394) 
Positive 
Negative 
 
1.83 (1.5,2.3) 
Reference 
 
1.05 (0.8,1.3) 
Reference 
 
1.2 (0.9,1.5) 
Reference 
HSV 23 (N=12379) 
Positive 
Negative 
 
2.3 (1.9,2.8) 
Reference 
 
1.12 (0.9,1.4) 
Reference 
 
1.3 (1.1,1.6) 
Reference 
Model 4 Odds of Prediabetes vs. Odds of Euglycemia 
HSV 12 (N=13807) 
Positive 
Negative 
 
1.8 (1.6,1.9) 
Reference 
 
1.12 (0.9,1.3) 
Reference 
 
1.3 (1.1,1.4) 
Reference 
HSV 23 (N=13787) 
Positive 
Negative 
 
1.9 (1.7,2.2) 
Reference 
 
1.03 (0.9,1.2) 
Reference 
 
1.2 (1.0,1.4) 
Reference 
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1: Models adjusted for Age, Gender, Race, Poverty ratio, BMI, Total Cholesterol, Current Smoking status, 
Hypertension, Protection use, Sex partners in a lifetime, Sex partners in a year and male circumcision 
status. 
2: Herpes Simplex Virus Type 1 status determined by testing participant serum for antibodies to herpes 
simplex type 1. The test was conducted by the National Health and Nutrition Examination Survey, US. 
3: Herpes Simplex Virus Type 2 test results determined by testing participant serum for antibodies to 
herpes simplex type 2. The test was conducted by the National Health and Nutrition Examination 
Survey, US.
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Table 5: 
Supplementary Multivariable models for odds of HSV 1 by diabetes mellitus status in 
United States population aged 18-49 years, 2007-2016: 
Models Adjusted Odds ratio (95% CI) 
for Diabetes1 vs. Prediabetes 
and No Diabetes  
Covariates3 
Model 1 
 HSV 12  (N=14599) 
Positive 
Negative 
1.03 (0.8,1.3) 
 
Age, Sex, Race, Poverty ratio, 
BMI, Total Cholesterol, HSV 2, 
Current Smoking status, 
Hypertension, marital status,  
Sex partners in a lifetime, Sex 
partners in a year and male 
circumcision status.  
HSV 22 (N=14599) 
Positive 
Negative 
1.11 (0.9,1.4) 
Model 2 
HSV 12 (N=14638) 
Positive 
Negative  
 
1.2 (0.9,1.5) 
Reference 
Age, Sex, Race, Marital Status, 
Sex partners in lifetime, Sex 
partners per year, Male 
circumcision HSV 22 (N=14618) 
Positive 
Negative 
 
1.3 (1.04,1.6) 
Reference 
Model 3 
HSV 12 (N=14638) 
Positive 
Negative 
 
1.1 (0.8,1.3) 
Reference 
Age, Sex, Race, BMI, Total 
Cholesterol, Lifetime Smoking 
status 
HSV 22 (N=14618) 
Positive 
Negative 
 
1.2 (0.9,1.4) 
Reference 
Model 4 
HSV 12 (N=14638) 
Positive 
Negative 
 
1.1 (0.9,1.4) 
Reference 
Age, Sex, Total cholesterol, 
Current smoking status, 
Hypertension 
HSV 22 (N=14618) 
Positive 
Negative 
 
1.2 (1.0,1.5) 
Reference 
Model 5 
HSV 12 (N=14638) 
Positive 
Negative 
 
1.4 (1.3,1.5) 
Reference 
Age, Sex, Total Cholesterol, 
Hypertension, BMI 
HSV 22 (N=14618) 
Positive 
Negative 
 
1.5 (1.3,1.7) 
Reference 
 
1: Individuals defined as prediabetes and no diabetes based on American Diabetes Association 
guidelines (16) were classified as No diabetes for models 
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2: Herpes Simplex Virus Type 1 status determined by testing participant serum for antibodies to herpes 
simplex type 1. The test was conducted by the National Health and Nutrition Examination Survey, US. 
3: Covariates controlled for in the multivariable logistic model. 
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